H
HalioDx
Biotech & Life Sciences · Marseille, France · Founded 2014
Providing oncologists and biopharma with first-in-class immune-based diagnostic products and services MoreLess
HalioDx was founded with a vision to revolutionize the field of precision medicine. The company was established by a team of innovative scientists and entrepreneurs, although specific names of the founders are not readily available. HalioDx focused on developing diagnostic solutions that enable personalized treatment for cancer patients, leveraging the power of immuno-oncology.
The company quickly gained recognition for its unique approach to diagnostics, which combined advanced biomarker technologies with a deep understanding of the tumor microenvironment. This allowed HalioDx to provide critical insights into how a patient's immune system interacts with cancer, thus guiding more effective treatment strategies.
A significant milestone in HalioDx's journey was its acquisition by Veracyte in 2021. This acquisition was a strategic move that expanded Veracyte's capabilities in the field of cancer diagnostics, integrating HalioDx's innovative solutions into its portfolio. The merger aimed to accelerate the development and commercialization of advanced diagnostic tests, ultimately improving patient outcomes in oncology.
Through its journey, HalioDx has remained committed to advancing precision medicine, continually pushing the boundaries of what is possible in cancer diagnostics. The company's story is a testament to the impact of innovative science and strategic partnerships in transforming healthcare.
Company overview
HalioDx company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Marseille, France
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 58.6
Valuation & funding
HalioDx funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2021 | $286M | $286M | Veracyte | — |
| SUPPORT PROGRAM✓Other financing | Oct 2019 | $2K | — | EIT Health | — |
| SERIES B✓Equity / VC | Jan 2018 | $20M | $81M | Bpifrance · Quest for Growth · MI Care S.A. · BNP Paribas | ↗ |
| SERIES A✓Equity / VC | Mar 2015 | $8.8M | $35M | Turenne Capital | — |
| SPINOUT✓Other financing | Jan 2014 | $0 | — | INSERM | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
HalioDx website traffic
Latest recorded traffic for HalioDx is 550 monthly website visits, up 27.9% over the last three months.
Comparisons
HalioDx compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
HalioDx's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where HalioDx has talent and traffic
In the news
Latest news about HalioDx
Recent press, funding announcements, and product moves mentioning HalioDx — open to read from the original sources.
Market sentiment
What the market is saying about HalioDx
An AI-synthesized read of the highest-engagement posts about HalioDx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HalioDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.